Market Overview - The pharmaceutical commercial sector experienced a decline of 0.22% on January 29, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Run Da Medical (603108) with a closing price of 16.43, up 2.88% and a trading volume of 455,600 shares, totaling 756 million yuan [1] - Da Shen Lin (603233) closed at 20.25, up 2.27% with a trading volume of 84,100 shares, totaling 170 million yuan [1] - Hua Ren Health (301408) closed at 22.35, up 0.81% with a trading volume of 267,500 shares, totaling 602 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 11.77, down 4.70% with a trading volume of 301,800 shares, totaling 357 million yuan [2] - Hai Wang Biological (000078) closed at 3.80, down 4.04% with a trading volume of 2,002,500 shares, totaling 771 million yuan [2] - Rui Kang Pharmaceutical (002589) closed at 3.40, down 2.86% with a trading volume of 757,500 shares, totaling 260 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 310 million yuan from major funds, while retail investors contributed a net inflow of 388 million yuan [2] - The detailed capital flow for selected stocks showed: - Run Da Medical had a net inflow of 61.41 million yuan from major funds, but a net outflow of 44.17 million yuan from retail investors [3] - Kyushu Tong (600998) experienced a net inflow of 20.92 million yuan from major funds, with a net outflow of 7.80 million yuan from retail investors [3] - Other stocks like Da Shen Lin and Lao Bai Xing also showed mixed capital flows with varying degrees of net inflows and outflows [3]

Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. is set to hold its first extraordinary general meeting of shareholders in 2026 on February 5, 2026, with both on-site and online voting options available [1][2]. Meeting Details - The meeting will take place on February 5, 2026, at 14:00 in Nanjing [1]. - The voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's voting system [1][2]. - The online voting will be available from 9:15 to 15:00 on the same day [2]. Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's network voting system, either through a trading terminal or an internet platform [6][7]. - Specific procedures apply for shareholders involved in margin trading, transfer, and other related accounts [3]. Agenda Items - The meeting will review several proposals, including special resolutions and matters requiring separate voting for minority investors [5][6]. - The proposals have been previously approved by the board meetings held on December 18, 2025, and January 19-20, 2026 [5]. Attendance and Registration - Shareholders registered by the close of trading on the registration date are entitled to attend the meeting [11]. - Registration for attendance will occur on February 4, 2026, with specific requirements for both corporate and individual shareholders [12][13]. Additional Services - To facilitate participation, the company will utilize a reminder service to notify shareholders about the meeting and voting options [7].

证券日报网讯1月28日，嘉事堂（002462）在互动平台回答投资者提问时表示，截至2026年1月20日，公 司股东共2.9万余户。 ...

Market Overview - The pharmaceutical commercial sector declined by 1.0% on January 28, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - China Medicine (600056) with a closing price of 11.21, up 2.28% and a trading volume of 531,600 shares, totaling 593 million yuan [1] - Yixin Pharmacy (002727) closed at 14.09, up 0.64% with a trading volume of 220,100 shares, totaling 311 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 12.35, down 4.93% with a trading volume of 432,700 shares, totaling 537 million yuan [2] - Saili Medical (603716) closed at 23.29, down 4.71% with a trading volume of 157,600 shares, totaling 374 million yuan [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 528 million yuan from institutional investors, while retail investors saw a net inflow of 603 million yuan [2] - The capital flow for key stocks showed: - China Medicine had a net inflow of 32.15 million yuan from institutional investors, but a net outflow of 15.57 million yuan from retail investors [3] - Shanghai Pharmaceutical (601607) had a net inflow of 9.01 million yuan from institutional investors, with a significant net outflow of 32.51 million yuan from retail investors [3]

Core Insights - The report indicates a recent adjustment in the A-share market, with major indices showing signs of stabilization and potential for upward movement if trading volumes increase [2][7][9] - Focus on structural opportunities is emphasized, particularly in blue-chip stocks and high-growth sectors, while caution is advised regarding stocks with uncertain earnings [2][8] Market Overview - On Tuesday, the three major indices opened lower but rebounded, with sectors such as precious metals, semiconductors, and insurance showing gains [3][4] - The overall market sentiment is described as average, with a total trading volume of 28,950 billion yuan, and the Shanghai Composite Index closing at 4,139.90 points, up 0.18% [4] Sector Analysis - The semiconductor sector has been highlighted for its strong performance, with a year-on-year increase of 10.10% in 2023, driven by digital transformation and geopolitical factors [5] - The precious metals sector continues to rise, supported by factors such as the Federal Reserve's interest rate cuts, increased geopolitical tensions, and strong demand from central banks [6] Future Market Outlook - The report suggests that if trading volumes continue to increase, there is a significant chance for the market to break through previous resistance levels [7][9] - It is recommended to focus on structural opportunities, particularly in blue-chip stocks and high-growth sectors, while avoiding stocks with high uncertainty in earnings [8]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]

重要新闻提示 宁波富邦：预计2025年归母净利润同比增长3099.59%—4379.43% 中微半导：发布涨价通知函，决定对MCU、Norflash等产品进行价格调整，涨价幅度15%—50% 嘉事堂：股东正筹划公司控制权变更事项，今起停牌 今日提示 科创板新股恒运昌（688785）、北交所新股农大科技（920159）今日上市 鸣鸣很忙今日在港交所挂牌上市，成为港股"量贩零食第一股" 央行公开市场今日有3635亿元逆回购到期 财政部、央行：今日进行2026年中央国库现金管理商业银行定期存款（一期）招投标 国新办今日上午10时举行新闻发布会，国务院国资委副主任庞骁刚介绍2025年国资央企高质量发展情 况，并答记者问 财经新闻 1.国家统计局1月27日发布数据显示，2025年，全国规模以上工业企业实现利润总额73982亿元，比上年 增长0.6%。 2.中国人民银行1月27日消息，中国人民银行日前召开2026年反洗钱工作会议。会议要求，2026年要充 分认识反洗钱工作面临的新形势新要求，认真做好当前和今后一段时期反洗钱重点工作。 具体看，一是持续推进反洗钱条线从严治党，坚持以高水平党建引领业务工作。 二是全力做好第五 ...

Core Viewpoint - The announcement from Jia Shitang indicates a potential change in its controlling shareholder and actual controller, leading to a temporary suspension of trading for up to two trading days starting January 28 [1][3]. Group 1: Company Overview - Jia Shitang is a major platform for China Everbright Group in the health sector, with its stock price at 16.40 CNY per share and a total market capitalization of 4.784 billion CNY as of January 27 [1][5]. - The major shareholders of Jia Shitang are China Everbright Medical Health Industry Co., Ltd. and China Everbright Industrial Group Co., Ltd., holding 14.36% and 14.12% of shares respectively [3][4]. Group 2: Financial Performance - Jia Shitang has experienced a continuous decline in performance, with net profits for the years 2022, 2023, and 2024 reported at 297 million CNY, 250 million CNY, and 161 million CNY respectively [8]. - The company's revenue for 2024 was approximately 24.02 billion CNY, a decrease of 19.93% from 2023, while net profit attributable to shareholders dropped by 35.75% to about 160.67 million CNY [10]. - For the first three quarters of 2025, the net profit attributable to shareholders decreased by 38.81% to 141 million CNY, with a significant drop in non-recurring profit as well [11].

【导读】嘉事堂控制权生变，自1月28日开市起停牌 1月27日晚间，嘉事堂发布公告称，公司控股股东、实际控制人可能发生变更，计划自1月28日开市起停牌，预计停牌时间不超过2个交 易日。 嘉事堂是中国光大集团股份公司（以下简称光大集团）在大健康业务板块的主要平台之一。截至1月27日收盘，嘉事堂股价报16.40元/ 股，下跌1.38%，总市值为47.84亿元。 電車東 8 17 002462 L1 ▼ 16.40 今开 16.60 最高 16.71 最低 16.00 -1.38% -0.23 换手⊙ 3.03% 总手 88426 金额 1.44亿 总值⊙47.84亿 流值 47.80亿 市盈型⊙25.39 更多 Eh 停复牌:自2026-01-28连续停牌,停牌原因:刊登重要 ... ● 分时 五日 日K 均线▼ MA5:16.58↑ 10:16.46↑ 20:16.37↑ DK点 | 前复权 19.69-> 19.69 18.07 16.45 14.82 主力意愿 ▼ 解锁查看完整K线数据 1143.43 -4343.84 20250916 20251031 20251212 20260127 "光大系"拟出让控 ...

【导读】嘉事堂控制权生变，自1月28日开市起停牌 1月27日晚间，嘉事堂（002462）发布公告称，公司控股股东、实际控制人可能发生变更，计划自1月28日开市起停牌，预计停牌时间 不超过2个交易日。 嘉事堂是中国光大集团股份公司（以下简称光大集团）在大健康业务板块的主要平台之一。截至1月27日收盘，嘉事堂股价报16.40元/ 股，下跌1.38%，总市值为47.84亿元。 "光大系"拟出让控制权 公告显示，中国光大实业（集团）有限责任公司（以下简称光大实业）及其全资子公司中国光大医疗健康产业有限公司（以下简称光 大医疗），正在筹划嘉事堂的股权转让事宜。 截至2025年第三季度末，光大医疗、光大实业分别为嘉事堂的第一、第二大股东，直接持股比例分别为14.36%、14.12%。 | 报告期末普通股股东总数 | | 22.745 | | 报告期末表决权恢复的优先股股东总数(如有) | | 0 | | --- | --- | --- | --- | --- | --- | --- | | | | | 前 10 名股东持股情况(不含通过转融通出借股份) | | | | | 股东名称 | 股东性质 | 持股比例 | 持股数 ...